Unhappy new year for Calithera
The company welcomes in 2021 with the failure of a pivotal study of its pipeline lead, telaglenastat.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Esmo 2019 preview – Parps on parade
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
